Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Acute myeloid leukemia is a heterogenous hematological malignancy, characterized by different
cytogenetic or molecular features. CEBPA double mutation acute myeloid leukemia （CEBPAdm
AML）has favourite prognosis, especially in younger adult patients. But cumulative incidence
of relapse of this group patients is still high, so the treatment options need to be
optimized urgently.HAD(homoharringtonine(HHT)+cytarabine+daunorubicin) with intermediate dose
cytarabine improved the survival of AML, especially in patients with CEBPA double mutation.